Edoxaban Tosylate Monohydrate: Handling & Assay Protocol
Edoxaban Tosylate Monohydrate: Handling & Assay Protocol
Edoxaban tosylate Monohydrate is a potent, selective, oral Factor Xa (FXa) inhibitor widely used as a research tool compound to study anticoagulation mechanisms and thromboembolic disease models in vitro and in vivo.
- Chemical Name
- Edoxaban tosylate Monohydrate (N-(5-Chloro-2-pyridinyl)-2-[[4-[(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxy-benzamide 4-methylbenzenesulfonate monohydrate)
- Primary Target
- Factor Xa (FXa) — direct, selective inhibitor
- Recommended Storage
- Store at -20 °C, protected from light and moisture; stable for ≥2 years when stored properly
- Solubility
- Soluble in DMSO (≥10 mM) and water; limited solubility in ethanol
- Purity
- ≥98% (HPLC)
- Research Application
- In vitro FXa activity assays, anticoagulation pharmacology, thrombus models
Materials and Safety Precautions
Before beginning work with Edoxaban tosylate Monohydrate (SKU: E172755), gather the following materials and review all relevant safety information:
- Compound: Edoxaban tosylate Monohydrate (E172755, Aladdin Scientific)
- Solvents: Anhydrous DMSO (tissue-culture grade), sterile phosphate-buffered saline (PBS, pH 7.4), or ultrapure water
- Equipment: Analytical balance (0.01 mg readability), vortex mixer, benchtop microcentrifuge, 0.22 µm syringe filters (PVDF), amber microcentrifuge tubes
- PPE: Lab coat, nitrile gloves, and safety glasses are required at all times
Safety Notes: Edoxaban tosylate Monohydrate is a pharmacologically active anticoagulant. Avoid inhalation of dust or aerosols. Consult the Safety Data Sheet (SDS) before use. As a research reagent, it is for in vitro and in vivo laboratory use only — not for human therapeutic use. Handle DMSO with care as it readily penetrates skin and may carry dissolved compounds transdermally.
Stock Solution Preparation
Follow the steps below to prepare a high-quality stock solution of Edoxaban tosylate Monohydrate:
- Equilibrate the vial: Allow the sealed vial to equilibrate to room temperature (approximately 15–20 minutes) before opening to prevent moisture condensation on the powder.
- Calculate the required volume: Determine the volume of solvent needed to achieve the desired stock concentration (typically 10–50 mM). Use the formula: Volume (mL) = Mass (mg) / [MW (g/mol) × Target concentration (mM) × 10-3]. The molecular weight of Edoxaban tosylate Monohydrate is approximately 738.22 g/mol.
- Dissolve in DMSO: Add the calculated volume of anhydrous DMSO directly to the vial. Vortex for 1–2 minutes, then sonicate in a water bath (25 °C, 5–10 minutes) if needed to ensure complete dissolution. The solution should be clear and colorless to pale yellow.
- Optional aqueous dilution: For aqueous working solutions, dilute the DMSO stock into PBS or culture medium. Keep the final DMSO concentration ≤0.1% (v/v) in cell-based assays to avoid cytotoxic artifacts. If precipitation occurs, warm the solution gently at 37 °C with vortexing.
- Filter sterilize: Pass the solution through a 0.22 µm PVDF syringe filter if sterility is required for cell-based work.
- Aliquot and store: Dispense into single-use amber microcentrifuge tubes. Store DMSO stocks at -20 °C (up to 6 months) or -80 °C for long-term storage. Avoid repeated freeze–thaw cycles.
Note: Always prepare fresh working dilutions on the day of the experiment from frozen aliquots.
In Vitro Factor Xa Inhibition Assay
This fluorometric or chromogenic assay measures the ability of Edoxaban tosylate Monohydrate to inhibit purified human Factor Xa (FXa) enzymatic activity.
Reagents Required
- Purified human Factor Xa (commercial source)
- Fluorogenic substrate (e.g., Boc-Ile-Glu-Gly-Arg-AMC) or chromogenic substrate (e.g., S-2222)
- Assay buffer: 50 mM Tris-HCl, 150 mM NaCl, 5 mM CaCl2, 0.1% BSA, pH 7.4
- 96-well black flat-bottom microplate (for fluorometric) or clear plate (for chromogenic)
- Microplate reader with appropriate filters
Procedure
- Prepare compound dilutions: Prepare a 10-point serial dilution series of Edoxaban tosylate Monohydrate in assay buffer (e.g., 0.1 nM – 1 µM final concentration range) from the DMSO stock. Maintain DMSO ≤0.1% (v/v) in all wells.
- Pre-incubation: Add 10 µL of compound solution (or vehicle control) to each well, followed by 40 µL of FXa solution (final enzyme concentration per validated assay conditions). Incubate at 37 °C for 15 minutes to allow compound–enzyme equilibration.
- Initiate reaction: Add 50 µL of fluorogenic or chromogenic substrate at the predetermined Km concentration to initiate the enzymatic reaction. Mix gently by plate shaking (30 seconds).
- Read signal: For fluorometric substrates, monitor fluorescence at Ex/Em = 380/460 nm at 37 °C over 30–60 minutes (kinetic mode). For chromogenic substrates, read absorbance at 405 nm.
- Calculate inhibition: Determine percent inhibition relative to vehicle-only control wells. Fit concentration–response data to a four-parameter logistic (4PL) curve to derive IC50 values.
Controls: Include (a) enzyme + substrate without compound (maximum activity), (b) substrate only without enzyme (background), and (c) a known FXa inhibitor reference standard for assay validation.
Troubleshooting
Use the following guidance to resolve common issues encountered when working with Edoxaban tosylate Monohydrate:
| Problem | Likely Cause | Suggested Solution |
|---|---|---|
| Compound does not dissolve completely | Insufficient vortexing or low temperature | Warm to 37 °C briefly and re-vortex; sonicate for 5–10 min; ensure DMSO is anhydrous |
| Precipitation in aqueous media | Solubility limit exceeded or rapid dilution into cold buffer | Reduce final compound concentration; pre-warm buffer to 37 °C before dilution; reduce DMSO concentration step-wise |
| Low or variable FXa inhibition signal | Enzyme loss of activity or substrate concentration outside linear range | Verify enzyme activity with positive control; confirm substrate is within linear range; check assay buffer pH and CaCl₂ concentration |
| High background fluorescence | DMSO concentration too high or compound autofluorescence | Keep DMSO ≤0.1% (v/v); measure compound fluorescence without substrate to subtract background |
| Irreproducible IC₅₀ values | Freeze–thaw degradation or inconsistent pre-incubation time | Use single-use aliquots; standardize all incubation times; run reference inhibitor in every plate |
Frequently asked questions
What is the best solvent for preparing Edoxaban tosylate Monohydrate stock solutions?
Anhydrous DMSO is the recommended primary solvent, typically yielding stock solutions of 10–50 mM. For aqueous applications, the DMSO stock should be diluted into PBS or culture medium with the final DMSO concentration kept at ≤0.1% (v/v). Water may also be used directly for lower concentration aqueous stocks.
How should Edoxaban tosylate Monohydrate be stored to maintain stability?
The solid compound should be stored at -20 °C in a desiccated, light-protected environment. Prepared DMSO stock solutions should be aliquoted into single-use amber tubes and stored at -20 °C (up to 6 months) or -80 °C for extended periods. Avoid repeated freeze–thaw cycles, which can accelerate degradation.
What concentration range is appropriate for FXa inhibition assays using this compound?
For IC50 determination, a 10-point serial dilution covering a final concentration range of approximately 0.1 nM to 1 µM is typically used. The precise range may need to be adjusted based on the specific enzyme source, assay buffer conditions, and substrate concentration employed. Always include a vehicle control and a reference inhibitor for each assay plate.
Is Edoxaban tosylate Monohydrate suitable for cell-based anticoagulation studies?
Yes, Edoxaban tosylate Monohydrate can be used in cell-based assays that measure FXa-dependent signaling or coagulation endpoints. Ensure the final DMSO concentration does not exceed 0.1% (v/v) to avoid cytotoxicity. Conduct a vehicle-only cytotoxicity control experiment before proceeding with pharmacological studies.
What quality specifications does Aladdin's E172755 meet?
Aladdin's Edoxaban tosylate Monohydrate (SKU: E172755) is supplied at ≥98% purity as determined by HPLC. Each lot is accompanied by a Certificate of Analysis (CoA) verifying identity, purity, and appearance. The compound is intended for research use only and is not certified for clinical or therapeutic applications.
References
- Furugohri T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6(9):1542–1549.
- Hokusai-VTE Investigators. Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. N Engl J Med. 2013;369(15):1406–1415.
- Giugliano RP, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2013;369(22):2093–2104.
Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
危险品化学品经营许可证（带存储）